Recent 8-K filings for IMA
Highest-materiality recent filing
Ikena Oncology completes merger with Inmagene, becomes ImageneBio, raises $75M private placement
- Merger closed July 25, 2025; combined company renamed ImageneBio, Inc., trading on Nasdaq under IMA starting July 28.
- Concurrent $75.0M private placement from investors including Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors.
-
ImageneBio Q1 net loss $10.6M; cash $117.2M, raised $30M in April private placement
Net loss of $10.6M for Q1 2026, vs $9.1M in Q1 2025; R&D $6.0M, G&A $6.1M.
-
Gross proceeds of ~$30M from sale of pre-funded warrants for 5.77M shares at $5.199 each.
-
ImageneBio PAO Erin Butler to depart; Bob Lally named as successor
Mutual separation of Erin Butler, SVP Finance & Administration and Principal Accounting Officer, effective March 20, 2026.
-
ImageneBio reports Q4 2025 net loss $6.9M; cash $135.3M; Phase 2b ADAPTIVE on track for 2027
Cash, equivalents and marketable securities: $135.3M at Dec 31, 2025 vs $12.1M at Dec 31, 2024, after merger and $75M private placement.
-
ImageneBio board member Steven Hui Wang resigns effective Feb 12, 2026
Steven Hui Wang resigned from the Board of Directors on February 12, 2026, effective immediately.
-
Imagenebio CMO Yufang Lu resigns effective Dec 31, 2025; search underway
Yufang Lu, M.D., Ph.D., Chief Medical Officer, resigned effective December 31, 2025.
-
ImageneBio updates corporate presentation; no new material details disclosed
Company released updated corporate presentation dated November 19, 2025.
-
ImageneBio reports Q3 net loss of $24.8M; advances Phase 2b AD trial with protocol amendment
Cash, equivalents, and marketable securities $142.6M as of Sep 30, 2025; net loss $24.8M for Q3 2025 vs $3.2M in Q3 2024; R&D $15.6M, G&A $11.0M.
-
ImageneBio appoints Joseph P. Slattery to Board and Audit Committee chair
Board size increased from 6 to 7; Slattery appointed director effective Nov 1, 2025.
-
Imagenebio terminates Miragene transition agreement; extends partial services for 6 months at $200K
Elected not to auto-renew transition services agreement with Miragene Inc. dated July 25, 2025.
-
ImageneBio CEO Kristin Yarema appointed interim principal financial officer
Board appointed CEO Kristin Yarema as interim CFO effective Oct 21, 2025.
-
CFO Jotin Marango resigns effective Oct 20; search for replacement begun
CFO Jotin Marango, M.D., Ph.D., resigned effective October 20, 2025.
-
ImageneBio files Inmagene pre-merger financials: $13.7M loss, going concern, $6M cash
Inmagene net loss of $7.6M in Q2 2025 and $13.7M in first half 2025; accumulated deficit $197.5M.
-
ImageneBio dismisses EY, appoints PwC as auditor effective Aug 2, 2025
Audit committee dismissed Ernst & Young LLP as independent auditor effective August 2, 2025.
-
ImageneBio adopts 2025 Inducement Plan, reserves 589,585 shares for new employee equity grants
Board approved 2025 Inducement Plan on July 28, 2025, reserving 589,585 shares for grants to new employees.
-
Merger closed July 25: Ikena acquired Inmagene, name changed to ImageneBio, ticker changes to IMA on Nasdaq Capital Market.
-
Ikena Oncology completes merger with Inmagene, becomes ImageneBio, raises $75M private placement
Merger closed July 25, 2025; combined company renamed ImageneBio, Inc., trading on Nasdaq under IMA starting July 28.
-
Ikena Oncology to effect 1-for-12 reverse stock split, rename to ImageneBio, ticker IMA
1-for-12 reverse stock split effective July 28, 2025; shares outstanding drop from ~48.2M to ~4M.
-
Ikena Oncology declares one-time CVR dividend; record date July 24, 2025
Board approved one contingent value right (CVR) per share of IKNA common stock.
-
Ikena Oncology amends executive’s equity vesting terms tied to pending Inmagene merger
Effective July 15, 2025, Ikena Oncology amended employment agreement with Dr. Jotin Marango, an executive officer.
-
Ikena stockholders approve Inmagene merger; 1:12 reverse split; combined co. to trade as IMA
All 7 proposals approved including merger issuance of IKNA shares >20% and reverse split.
-
ISS and Glass Lewis recommend Ikena stockholders vote FOR Inmagene merger
Institutional Shareholder Services (ISS) and Glass Lewis recommend voting FOR share issuance related to merger with Inmagene.
-
IMG-007 targets OX40 receptor with silenced ADCC to minimize safety risks and extended half-life for convenient dosing.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.95 · Median 0.55 · Most common event other_material